Bank of New York Mellon Corp Acquires 507,147 Shares of Sotera Health (NASDAQ:SHC)

Bank of New York Mellon Corp boosted its position in shares of Sotera Health (NASDAQ:SHC) by 45.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,630,736 shares of the company’s stock after buying an additional 507,147 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.58% of Sotera Health worth $22,308,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after buying an additional 1,140 shares during the last quarter. True Wealth Design LLC bought a new stake in Sotera Health during the 3rd quarter valued at $32,000. GAMMA Investing LLC raised its holdings in Sotera Health by 37.5% during the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock valued at $56,000 after buying an additional 1,121 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Sotera Health during the 3rd quarter valued at $259,000. Finally, Oak Thistle LLC purchased a new position in Sotera Health during the 4th quarter valued at $222,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Stock Down 2.9 %

Shares of Sotera Health stock opened at $11.81 on Tuesday. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The company has a 50-day moving average of $13.25 and a 200 day moving average of $14.37. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of 47.24 and a beta of 1.92. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.08.

Analysts Set New Price Targets

SHC has been the topic of a number of research analyst reports. Barclays reduced their price objective on shares of Sotera Health from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.92.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.